Switch to belatacept in kidney graft recipients.
نویسندگان
چکیده
associated with olmesartan. Aliment Pharmacol Ther. 2014;40:16–23. 4. DeGaetani M, Tennyson CA, Lebwohl B, Lewis SK, Abu Daya H, Arguelles-Grande C, et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013;108:647–53. 5. Ulla-Rocha JL, Lopez-Pineiro S, Puga-Gimenez M. Acute renal failure secondary to diarrhea due to sprue like-enteropathy associated with olmesartan. Gastroenterol Hepatol. 2015;38:514–5. 6. van Beurden YH, Nijeboer P, Janssen J, Verbeek WH, Mulder CJ. Diarrhoea and malabsorption due to olmesartan use. Ned Tijdschr Geneeskd. 2014;158:A7370. 7. Koizumi T, Furuya K, Baba M, Sadaoka K, Sekiya C, Hattori A. Case report; Olmesartan associated enteropathy: a case of severe watery diarrhea with weight loss and acute renal failure. Nihon Naika Gakkai Zasshi. 2015;104:1167–72. 8. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31. 9. Tellez Villajos L, Crespo Perez L, Cano Ruiz A, Moreira Vicente V. Enteropathy by olmesartan. Med Clin (Barc). 2015;144:140–1. 10. FDA. Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. http://www.fda.gov/Drugs/DrugSafety/ ucm359477.htm.
منابع مشابه
Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
BACKGROUND AND OBJECTIVES Prolonged use of calcineurin inhibitors (CNIs) in kidney transplant recipients is associated with renal and nonrenal toxicity and an increase in cardiovascular risk factors. Belatacept-based regimens may provide a treatment option for patients who switch from CNI-based maintenance immunosuppression. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS This is a randomized, ...
متن کاملTen Years Experience With Belatacept-Based Immunosuppression After Kidney Transplantation
BACKGROUND Belatacept was approved for prevention of acute rejection in adult kidney transplantation in 2011 based on two randomized, controlled, multicenter phase 3 studies. Long-term experience over 10 years with belatacept-based immunosuppression after kidney transplantation has not been reported before. PATIENTS AND METHODS Analyzed were 20 patients who had been included into a randomized...
متن کاملBelatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.
BACKGROUND AND OBJECTIVES Renal transplant recipients with pre-existing diabetes (PD) have reduced graft survival and increased risk of mortality and ischemic heart disease compared with nondiabetic transplant recipients. To assess the effect of belatacept in this high-risk group, we evaluated outcomes of the subpopulation with PD from previously published BENEFIT and BENEFIT-EXT trials. DESI...
متن کاملT-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade.
BACKGROUND Belatacept is thought to disrupt the interaction between CD80/86 and CD28, thus preventing T-cell activation by blocking the co-stimulatory second signal. However, the consequences on the T-cell profile in human renal transplant cases have not been determined. METHODS In this study, we analysed intra-graft levels of the mRNAs for Treg (FOXP3), cytotoxic CD8 T cells (Granzyme B), Th...
متن کاملBelatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study
This exploratory phase II study evaluated the safety and efficacy of belatacept in de novo adult liver transplant recipients. Patients were randomized (N = 260) to one of the following immunosuppressive regimens: (i) basiliximab + belatacept high dose [HD] + mycophenolate mofetil (MMF), (ii) belatacept HD + MMF, (iii) belatacept low dose [LD] + MMF, (iv) tacrolimus + MMF, or (v) tacrolimus alon...
متن کاملEarly Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome
Background Kidney transplantation is the first-line therapy for patients with end-stage renal disease since it offers greater long-term survival and improved quality of life when compared to dialysis. The advent of calcineurin inhibitor (CNI)-based maintenance immunosuppression has led to a clinically significant decline in the rate of acute rejection and better short-term graft survival rates....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia
دوره 37 5 شماره
صفحات -
تاریخ انتشار 2017